AGM
NAVB

Alpine Global Management’s Navidea Biopharmaceuticals Inc. NAVB Stock Holding History

Alpine Global Management’s Portfolio NAVB Stock Details NAVB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-10,158
Closed -$108K – 205
2016
Q2 		$108K Buy
+10,158
New +$200K 0.05% 127

Other funds holding NAVB

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $14.7B AUM 47% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
California Public Employees Retirement System
California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return

Alpine Global Management's NAVB Position: Q3 2016 in Review

Alpine Global Management sold out of Navidea Biopharmaceuticals Inc. (NAVB) in Q3 2016, closing a stake of 10,158 shares — an estimated $108K sold.

Alpine Global Management first reported a position in NAVB in Q2 2016 and held it in 1 quarter. The position peaked at $108K in Q2 2016. 55 funds tracked by Wall St. Rank hold NAVB as of Q3 2016.

  • Alpine Global Management reported no remaining Navidea Biopharmaceuticals Inc. position as of Q3 2016 after selling out during the quarter.
  • Alpine Global Management sold 10,158 Navidea Biopharmaceuticals Inc. shares in Q3 2016, an estimated $108K.
  • Alpine Global Management first reported a position in Navidea Biopharmaceuticals Inc. in Q2 2016 and held it in 1 quarter.
  • Alpine Global Management's Navidea Biopharmaceuticals Inc. position peaked at $108K in Q2 2016.
  • 55 funds tracked by Wall St. Rank held Navidea Biopharmaceuticals Inc. as of Q3 2016.

Based on Alpine Global Management's 13F filing for Q3 2016, filed 15 Nov 2016.